Every material Form 8-K Arcus Biosciences filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Arcus Biosciences entered into a First Amendment to its August 27, 2024 Loan and Security Agreement with Hercules Capital and the lenders, which governs the remaining $150.0 million of term loan commitments. The amendment ties the timing of future borrowing to set dates and to clinical and regulatory milestones, extends the maturity date to September 1, 2030, and adds performance covenants that apply if term loan advances exceed $200.0 million.
Maturity date extended to September 1, 2030, with no further extension right.
Remaining $150.0 million of term loan commitments: $25.0 million available through March 15, 2026, $25.0 million through September 15, 2026, and up to $50.0 million each after a Phase 3 Clinical Milestone and after FDA approval (Milestone I
Covenants apply if advances exceed $200.0 million, starting with quarterly statements three quarters after Milestone I: market capitalization of at least $1.5 billion plus Qualified Cash of at least 50.0% of secured obligations, or Qualifie
Arcus Biosciences reported third-quarter 2025 revenue of $26 million, down from $48 million a year earlier, and a net loss of $135 million, up from $92 million. Research and development spending rose to $141 million as late-stage trials expanded, and cash, cash equivalents and marketable securities were $841 million at September 30, 2025, down from $992 million at December 31, 2024. The company expects full-year 2025 GAAP revenue of $225 million to $235 million, and it said it has paused recruitment in the Phase 1b portion of the eVOLVE-RCC02 study.
Q3 2025 revenue was $26 million, compared with $48 million in Q3 2024, mainly due to a $15 million license payment in the prior year
Q3 2025 net loss was $135 million, compared with $92 million in Q3 2024
Cash, cash equivalents and marketable securities were $841 million at September 30, 2025, versus $992 million at December 31, 2024
Full-year 2025 GAAP revenue is expected to be between $225 million and $235 million
Arcus Biosciences reported second-quarter 2025 revenue of $160 million, up from $39 million a year earlier, and broke even on a net basis after a $93 million net loss in the same quarter of 2024. Most of the revenue increase came from a $143 million cumulative catch-up tied to pausing etrumadenant development and Gilead returning its license, so shareholders should weigh that one-time item against the six-month net loss, which widened to $112 million from $97 million.
Q2 2025 total revenue was $160 million versus $39 million in Q2 2024, including a $143 million cumulative catch-up tied to etrumadenant.
Q2 2025 net income was $0 versus a $93 million net loss in Q2 2024; the six-month net loss was $112 million versus $97 million.
Cash, cash equivalents and marketable securities were $927 million at June 30, 2025, compared with $992 million at December 31, 2024.
Arcus expects full-year 2025 GAAP revenue of $225 million to $235 million and expects R&D expenses to decline starting in Q4 2025.
Arcus Biosciences reported first-quarter 2025 revenue of $28 million, down from $145 million a year earlier, and a net loss of $112 million, compared with $4 million in the same period of 2024. The company said it expects GAAP revenue of $75 million to $90 million for full-year 2025, and it ended the quarter with $1.0 billion in cash, cash equivalents and marketable securities.
Revenue was $28 million versus $145 million a year earlier; license and development services revenue was $20 million versus $135 million.
Net loss was $112 million, or $1.14 per share, versus a net loss of $4 million, or $0.05 per share, in the first quarter of 2024.
R&D expenses rose to $122 million from $109 million, driven by early-stage and preclinical program activity.
Full-year 2025 GAAP revenue is expected to be between $75 million and $90 million.
Arcus Biosciences reported fourth-quarter and full-year 2024 results. Full-year revenue rose to $258 million from $117 million and the net loss narrowed to $283 million from $307 million, or $3.14 per share versus $4.15. The company ended the year with $992 million in cash, cash equivalents and marketable securities after completing a $150 million financing, though fourth-quarter net loss widened to $94 million from $81 million.
Full-year 2024 revenue was $258 million, compared with $117 million in 2023
Full-year net loss per share was $3.14, compared with $4.15 in 2023; full-year R&D expenses were $448 million, compared with $340 million
Fourth-quarter 2024 net loss was $94 million, compared with $81 million, on revenue of $36 million versus $31 million
Cash, cash equivalents and marketable securities were $992 million as of December 31, 2024, excluding proceeds from the $150 million financing
Gilead Sciences' time-limited exclusive option to casdatifan expired without exercise, so Gilead has no future rights to the program and Arcus retains full global development and commercial rights, subject to Taiho's option for Japan and certain other Asian countries (excluding China). Arcus also reported preliminary cash, cash equivalents and marketable securities of approximately $992 million as of December 31, 2024, which remains unaudited and subject to closing procedures.
Gilead's casdatifan option expired without exercise, as announced February 18, 2025; Gilead has no future rights to casdatifan.
Taiho Pharmaceutical's option right covers its territory, limited to Japan and certain other Asian countries (excluding China).
Preliminary cash, cash equivalents and marketable securities were approximately $992 million as of December 31, 2024, unaudited and may change.
ARC-20 data reported February 15, 2025 (data cut-off January 3, 2025): confirmed ORR of 33% (9) in the 100mg QD cohort of 27 patients.
Arcus Biosciences reported that Merdad Parsey resigned from its Board of Directors on February 6, 2025, in connection with his departure from Gilead Sciences. The Board the same day appointed Dietmar Berger, who joined Gilead in January 2025 as its Chief Medical Officer, as a Class II director to fill the vacancy; the filing says Gilead's board designee arrangement governs the timing of the change.
Merdad Parsey resigned from the Arcus Board, effective upon appointment of Gilead's new director designee under the Amended and Restated Investor Rights Agreement dated January 29, 2024.
Dietmar Berger was appointed as a Class II director on February 6, 2025.
Dr. Berger will receive no compensation for Board service; Arcus expects to enter its standard indemnification agreement with him.
Arcus Biosciences said Richard Markus, M.D., Ph.D. will become Chief Medical Officer effective January 31, 2025, and that Dimitry Nuyten, M.D., Ph.D. will leave the company on the same date. Nuyten entered into a separation agreement under the company's Severance Benefits Plan that includes a lump sum payment equal to 12 months of base salary, COBRA coverage for up to 12 months, and an additional cash payment tied to his 2024 annual bonus. The filing does not disclose the dollar amounts of these payments.
Richard Markus, M.D., Ph.D. appointed Chief Medical Officer, effective January 31, 2025
Dimitry Nuyten, M.D., Ph.D. departs January 31, 2025
Severance includes a lump sum equal to 12 months of base salary and COBRA coverage for up to 12 months
Additional cash payment tied to Nuyten's 2024 annual bonus; the final separation agreement will be filed after execution
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Arcus Biosciences filing is on SEC EDGAR ↗. 8-K briefs of other companies →